EXPERTS IN INSECT, MAMMALIAN AND BACTERIAL EXPRESSION
About OET partners
At Oxford Expression Technologies Ltd (OET), we work closely with many partners in biotechnology, pharmaceuticals and other research fields. We are proud of our stellar reputation as a global industry leader in Baculovirus protein expression and we are leader supplier of Baculovirus expression products for many of our worldwide partners. Contact us to find out more or view some of our partners below.
Oxford Brookes University
OET works closely with the Oxford Brookes University Insect Virus Research Group (IVRG) within the School of Biological & Molecular Sciences. The IVRG is co-located with OET in a purpose-built suite of modern laboratories which are well equipped for many aspects of molecular biology and virology. The group also has access to all School facilities including a state-of-the-art microscopy suite for confocal and electron microscopy. The long-standing relationship between the two organisations facilitates the transfer of specialist knowledge and techniques in order to overcome the more challenging aspects of each other’s research.
Trenzyme are a German based Contract Research Organisation who specialise in the development of assay cell lines, production cell lines and recombinant protein production. Since their establishment they have been a valued research partner of both national and international clients, ranging from academia and small biotechs to big pharmaceutical companies. OET’s collaboration with Trenzyme enables us to offer our customers a more comprehensive choice of recombinant protein expression platforms that cover not only the baculovirus system but also bacteria, yeast and mammalian.
ParaTechs Inc and OET have joined forces to bring together the benefits of OET’s baculovirus expertise with Paratechs’ innovative and unique product design capabilities. Through such collaborations, ParaTechs has allowed for the discovery and development of many widely used and revolutionary technologies, helping to make rapid advancements in the field of biological research. This partnership has already led to the establishment of the Super-Sf9 specialised insect cell lines and one-of-a-kind vankyrin expression vectors both of which are designed to be fully compatible with our flashBACTM system.
The European Collection of Authenticated Cell Cultures
The European Collection of Authenticated Cell Cultures (ECACC) has become one of the premier suppliers of authenticated and quality-controlled cell lines and nucleic acids in the world. The collection currently holds cell lines representing 45 different species, 50 tissue types, 300 HLA types, 450 monoclonal antibodies and at least 800 genetic disorders. ECACC is a centre of excellence and expertise in all aspects of cell culture and OET are pleased to announce that our partnership will be able to offer a combined baculovirus expression service with scaled up recombinant protein production in animal cell culture for quantities from 1L to multiples of 100L.
Oxfordshire Bioscience Network
OET is an active member of the Oxfordshire BioScience Network (OBN). OBN is a not-for-profit membership organisation which provides comprehensive support for the UK’s life sciences companies, corporate partners and investors. From this membership OET can benefit from OBN’s extensive networking, training and partnering opportunities not only in and around Oxfordshire but across the UK.
The Jenner Institute
The Jenner Institute is a partnership between the University of Oxford and The Pirbright Institute that supports the development of innovative vaccines against major global diseases affecting both humans and livestock. The institute focuses on rapid early-stage development of potential new vaccines and their assessment in clinical trials. This experience and expertise will help OET in successfully taking our vital work on Crimean Congo Haemorrhagic Fever virus (CCHFv) to candidate vaccine phase I clinical trials.
UK Health Security Agency
OET have partnered with UK Health Security Agency Virology and Pathogenesis Group to work jointly on developing an effective vaccine against Crimean Congo Haemorrhagic Fever virus (CCHFv). HSA is an operationally autonomous executive agency of the Department of Health. Their mission is to protect and improve the nation’s health and to address inequalities through working with, national and local government, the NHS, industry, and the voluntary and community sector.
Marlow Associates Ltd
OET have brought on consultancy company Marlow Associates to provide key advice and guidance in ensuring successful preparation for transfer of our CCHF vaccine technology to cGMP standards. Marlow Associates are experts in the requirements for production of Investigational Medicinal Products (IMPs) in the EU and US. Their consultancy services specialise in working towards regulatory approvals for early phase development of innovative biological and biotechnology based products.
The Newton Fund builds research and innovation partnerships with partner countries to support their economic development and social welfare, and to develop their research and innovation capacity for long-term sustainable growth. The UK’s Newton Fund money is classed as Official Development Assistance (ODA) and projects must demonstrate that they aim to improve the health and well-being of the population of Newton Fund countries through their actions. OET have been fortunate enough to secure such funding as part of a research partnership between the UK and Mexico which will focus on establishing an islet cell isolation and transplantation programme (TRANSDIA) for type I diabetes.
Innovate UK is the UK’s innovation agency and works towards driving UK productivity and growth by supporting businesses to realise the potential of new technologies. This is achieved by promoting the development and commercialisation of new ideas, connecting innovators with suitable partners, and offering advice and guidance on building successful businesses. OET is supported and funded by Innovate UK to help realise the potential of our vaccine technology for eradicating Crimean Congo Haemorrhagic Fever virus (CCHFv).
Expression Systems LLC
Headquartered in Davis, California, Expression Systems LLC is dedicated to supplying and servicing the baculovirus, cell culture and bio-industrial markets with innovative media formulations, complementary products and contract services. Expression Systems is a GMP facility compliant to Cell Culture Media Manufacturing: 21 CFR Part 820. Our partnership with ES allows us to offer their various baculovirus cell culture media to our customers in quantities from 1L upwards and their supplementary reagents and additives designed to improve virus infection and protein production.
Vaxine Pty Ltd
Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant. Supported by funding contracts from the National Institutes of Health Vaxine has developed a broad range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. OET is delighted to be working with Vaxine on a project funded by Innovate UK for the development of a new and innovative vaccine for Covid-19.
Virology Lab Wageningen University
Wagneningen university is based in the Netherlands and is one of the top universities in the world. OET have always had a close relationship with the university and have collaborated on a number of projects. Currently we are both working together on the NanoZoo project that utilises the baculovirus expression system to produce surface antigens of viral pathogens of farm animals (chickens and pigs) to develop novel vaccines.